Blueprint Medicines (BPMC) PT Raised to $125 at H.C. Wainwright
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $105.46 -2.4%
Rating Summary:
19 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 16 | New: 33
Rating Summary:
19 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 16 | New: 33
Join SI Premium – FREE
H.C. Wainwright analyst Andrew Fein raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $125.00 (from $85.00) while maintaining a Buy rating.
You May Also Be Interested In
- Stephens Starts Blueprint Medicines (BPMC) at Overweight
- Cellectar Biosciences (CLRB) PT Raised to $13 at Oppenheimer
- HSBC Upgrades Shanghai Pudong Development Bank Co Ltd. (600000:CH) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
